Female Hair Loss: Why Treatment Protocols Differ

Why different

Why Female Hair Loss Needs a Different Approach

Male pattern hair loss is overwhelmingly androgenetic alopecia driven by DHT sensitivity. The diagnostic question is usually simple; the treatment question is well-defined (finasteride, minoxidil, transplant).

Female hair loss is a much wider differential. Iron deficiency, thyroid disease, postpartum effluvium, PCOS, autoimmune (alopecia areata, lupus), chronic stress, crash dieting, GLP-1 weight loss, scarring alopecias (lichen planopilaris, frontal fibrosing alopecia), and medication-induced shedding can all present similarly.

A dermatologist's first job in female hair loss is the workup. Jumping straight to a treatment without the right diagnosis is a common reason women report feeling unheard or under-treated.

Differential

The Main Diagnoses to Distinguish

• ·Female pattern hair loss (FPHL): the female equivalent of androgenetic alopecia, with diffuse central thinning and a preserved frontal hairline. Often progressive.
• ·Telogen effluvium: diffuse shedding triggered 2–4 months after a stressor — illness, surgery, postpartum, severe diet, GLP-1 weight loss, certain medications. Usually self-limited if the trigger resolves.
• ·Iron deficiency: low ferritin (below 30–50 ng/mL by most dermatology references) can independently drive shedding even without overt anemia.
• ·Thyroid disease: both hypo- and hyperthyroidism cause hair shedding.
• ·PCOS-driven androgenetic loss: associated with hirsutism, acne, irregular cycles, and elevated androgens.
• ·Postpartum effluvium: 2–4 months after delivery, usually self-resolving by 12 months.
• ·Scarring alopecias (lichen planopilaris, frontal fibrosing alopecia, central centrifugal cicatricial alopecia): require early recognition because scarring is irreversible.
• ·Alopecia areata: autoimmune patchy loss, distinct treatment pathway.

Workup

Standard Dermatology Workup

• ·History: timing, triggers, family history, medications, menstrual and reproductive history, dietary patterns, recent weight loss.
• ·Scalp examination including dermoscopy/trichoscopy.
• ·Labs: ferritin (target >50 ng/mL for hair growth), TSH and free T4, CBC, vitamin D, and androgen panel (total and free testosterone, DHEA-S, SHBG) where indicated.
• ·For suspected scarring alopecia: scalp biopsy.
• ·Pull test, hair density assessment, and photodocumentation at baseline.

Treatment

Treatment Protocols in 2026 Dermatology Practice

Treatment is often combination, individualized to the diagnosis:

• ·Iron and thyroid optimization first if either is abnormal. No topical or systemic hair therapy works well if these are uncorrected.
• ·Low-dose oral minoxidil (typically 0.625–2.5 mg daily): first-line for FPHL and many forms of effluvium. See our dedicated oral minoxidil guide.
• ·Topical minoxidil 5% (often once daily for women given irritation): adjunct or first-line for patients who decline oral.
• ·Spironolactone (typically 50–200 mg daily): for androgen-driven FPHL, particularly with concurrent PCOS or hirsutism.
• ·Finasteride or dutasteride off-label: increasingly used in post-menopausal patients; requires informed consent for teratogenicity and is generally avoided in pre-menopausal patients of reproductive potential.
• ·PRP for select patients with FPHL who want a procedural adjunct.
• ·For scarring alopecia: anti-inflammatory therapy (intralesional steroids, hydroxychloroquine, etc.) — distinct treatment paradigm.

GLP-1 connection

GLP-1 Weight Loss and Female Hair Shedding

A subset of women on Ozempic, Wegovy, Mounjoro, or Zepbound experience telogen effluvium 2–4 months into rapid weight loss. The mechanism is rapid weight loss itself, not the drug — but the experience is real, often distressing, and frequently presents in dermatology offices.

Treatment combines protein optimization, iron repletion if low, and often a course of low-dose oral minoxidil to shorten the shedding window. See our dedicated GLP-1 hair loss guide.